Literature DB >> 16606982

Polymerase chain reaction and molecular genotyping to monitor parasitological response to anti-malarial chemotherapy in the Peruvian Amazon.

Everick Ayala1, Andrés G Lescano, Robert H Gilman, Maritza Calderón, Viviana V Pinedo, Hilja Terry, Lilia Cabrera, Joseph M Vinetz.   

Abstract

Over the past decade, anti-malarial drug resistance has rapidly become a major public health problem in the Peruvian Amazon. This study compared polymerase chain reaction (PCR) to light microscopy for diagnosing and monitoring the parasitological response of malaria patients to anti-malarial chemotherapy in the Peruvian Amazon region of Iquitos. Typing of P. falciparum using MSP1, MSP2, and glutamine-rich protein distinguished among infecting parasites. Most (73%) P. falciparum patients were parasitologically resistant to sulfadoxine-pyrimethamine (RI = 10, RII = 1). Sensitivity of microscopy was lower than PCR (69% for P. vivax and 78% for P. falciparum), but parasite clearance times were comparable between microscopy and PCR. PCR sensitively and specifically detected mixed infections and low-level parasitemia indicative of drug resistance, making this approach of practical use for the control of malaria at the public health level. Genotyping malaria parasites will be useful to distinguish drug failure from new infections in clinical trials of anti-malarial drugs in the Peruvian Amazon region.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606982

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.

Authors:  Zhiyong Zhou; Sean M Griffing; Alexandre Macedo de Oliveira; Andrea M McCollum; Wilmer Marquino Quezada; Nancy Arrospide; Ananias A Escalante; Venkatachalam Udhayakumar
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

2.  High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan.

Authors:  I E A-Elbasit; I F Khalil; M I Elbashir; E M Masuadi; I C Bygbjerg; M Alifrangis; H A Giha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-29       Impact factor: 3.267

3.  PCR detection of Plasmodium falciparum in human urine and saliva samples.

Authors:  Sungano Mharakurwa; Christopher Simoloka; Philip E Thuma; Clive J Shiff; David J Sullivan
Journal:  Malar J       Date:  2006-11-08       Impact factor: 2.979

4.  Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine.

Authors:  David J Bacon; Doug Tang; Carola Salas; Norma Roncal; Carmen Lucas; Lucia Gerena; Lorena Tapia; A Alejandro Llanos-Cuentas; Coralith Garcia; Lelv Solari; Dennis Kyle; Alan J Magill
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

5.  Distinction of Plasmodium falciparum recrudescence and re-infection by MSP2 genotyping: a caution about unstandardized classification criteria.

Authors:  Petrica Rouse; Mtawa Ap Mkulama; Philip E Thuma; Sungano Mharakurwa
Journal:  Malar J       Date:  2008-09-23       Impact factor: 2.979

6.  Comparison of PCR-based detection of Plasmodium falciparum infections based on single and multicopy genes.

Authors:  Segun I Oyedeji; Henrietta O Awobode; Gamaliel C Monday; Eric Kendjo; Peter G Kremsner; Jürgen F Kun
Journal:  Malar J       Date:  2007-08-16       Impact factor: 2.979

7.  Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria.

Authors:  Spencer D Polley; Iveth J González; Deqa Mohamed; Rosemarie Daly; Kathy Bowers; Julie Watson; Emma Mewse; Margaret Armstrong; Christen Gray; Mark D Perkins; David Bell; Hidetoshi Kanda; Norihiro Tomita; Yutaka Kubota; Yasuyoshi Mori; Peter L Chiodini; Colin J Sutherland
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.